Company intelligence / Profile preview

Orygen

São Paulo, São Paulo, Brazilorygen.org.au ↗

Ownership: Private
Development stage: Commercial

Overview

Orygen develops innovative biopharmaceuticals with a focus on immunological products using its proprietary Hiltonol® platform. The company also develops biosimilar monoclonal antibodies and vaccines aimed at improving access within Brazil’s public health system. It has established partnerships with major Brazilian pharma companies and international collaborators for manufacturing and technology transfer.

Therapeutic areas: OtherImmunology
Modalities: Monoclonal antibodyVaccineImmunostimulant/Adjuvant
Industry: Biotech

Partnerships

Eurofarma Laboratórios SABiolab Sanus Farmaceutica LtdaEPIRUS Biopharmaceuticals Inc.Academic collaborations with universities in Latin America

Beyond the preview

Go deeper on Orygen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Orygen.

Explore the full profile